Added Value of the Neuropsychological Evaluation for Diagnosis and Research of Atypical Parkinsonian Disorders

Size: px
Start display at page:

Download "Added Value of the Neuropsychological Evaluation for Diagnosis and Research of Atypical Parkinsonian Disorders"

Transcription

1 Added Value of the Neuropsychological Evaluation Added Value of the Neuropsychological Evaluation for Diagnosis and Research of Atypical Parkinsonian Disorders Bruno Dubois and Bernard Pillon INTRODUCTION Diseases with movement disorders may be difficult to diagnose, both at the onset when motor symptoms are mild and not sufficiently specific (e.g., difficulty in manipulating objects), or at the end stage when distinctive motor signs are diluted into a severe and polymorphous clinical picture (e.g., gait disorder with postural instability and cognitive decline in aged patients). Erroneous diagnoses are frequent (1,2), even in the most common idiopathic Parkinson s disease (PD) (3). Some of these errors may be avoided if the cognitive dysfunctions that often accompany these diseases are included in the diagnostic criteria. Subtle but specific cognitive deficits can frequently be detected in patients with a variety of diseases accompanied by movement disorders. We used to say except for essential tremor but some cognitive changes have recently been reported even in this case (4). This is explained by the fact that the neuronal pathways connecting the basal ganglia to the cortex project not only to regions involved in the control of movements (motor, premotor, supplementary motor areas) but also to cortical areas contributing to cognitive functions (prefrontal cortex) and to emotional-processing behavior (cingulum and orbitofrontal cortex). In each of these diseases, the loss of different specific populations of neurons in the basal ganglia produces not only a characteristic motor syndrome, but also a recognizable pattern of neuropsychological deficits. Why not include these cognitive and behavioral changes in diagnosis decision trees? Indeed, the use of appropriate neuropsychological tests or questionnaires to detect these deficits can contribute to the diagnosis of such diseases (Table 1). In this review, we will (1) present the different types of deficits that can be usually encountered following lesions of the basal ganglia; (2) characterize the neuropsychological pattern of the main movement disorders: idiopathic PD, multiple system atrophy (MSA), progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), and dementia with Lewy bodies (DLB); and (3) show that the contribution of neuropsychological deficits to diagnosis varies from one parkinsonian disorder to another. From: Current Clinical Neurology: Atypical Parkinsonian Disorders Edited by: I. Litvan Humana Press Inc., Totowa, NJ 185

2 186 Dubois and Pillon Table 1 Proposed Neuropsychological Battery to Evaluate Cognitive and Behavioral Deficits in Parkinsonian Disorders Domain of Investigation Proposed Tool Global cognitive efficiency Mattis Dementia Rating Scale (5) Global executive syndrome Frontal Assessment Battery (6) Set elaboration and monitoring Wisconsin Card Sorting Test (7) Set maintenance Lexical fluency (8) Set shifting Trail Making Test (9) Inhibition of interferences Stroop Test (10) Motor programming Graphic and motor series (11) Resistance to environmental dependency Imitation, prehension, utilization (12) Strategic components of memory California Verbal Learning Test (13) Opposition between free and cued recall Grober and Buschke Test (14) Linguistic functions Boston Diagnostic Aphasia Examination (15) Gestures Apraxia examination (16) Emotional behavior Neuropsychiatric Inventory (17) WHAT ARE THE COGNITIVE AND BEHAVIORAL CHANGES CURRENTLY ENCOUNTERED IN PARKINSONIAN DISORDERS? The neuropsychological picture of patients may vary from subtle behavioral abnormalities to florid dementia with delusions and hallucinations. The nature and severity of cognitive disorders, the type of impaired memory processes, the presence or absence of instrumental deficits, the precocity of the dysexecutive syndrome, and the frequency of behavioral disorders depend on the underlying neuronal lesions. Dementia According to DSM-IV (Diagnostic and Statistical Manual of Mental Disorders, 4th ed.) criteria (18), dementia is defined by the development of multiple cognitive deficits, severe enough to interfere with social activity or personal relationships and representing a decline from a previously higher level of functioning. The term dementia needs to be used with caution in diseases in which motor impairment, mood, and behavioral disorders may be part of the clinical picture. In these patients the loss of intellectual capacities can, however, be evaluated by psychometric criteria, using global scales, such as the Mattis Dementia Rating Scale (5), which is more appropriate than the Mini Mental State Exam for predominantly subcortical degenerative diseases, given the inclusion of tests evaluating attention and executive functions. Such tools provide cutoff scores that permit a psychometric distinction between demented and nondemented patients. Dementia is usually not observed in PD with early onset (19) or in the early stages of PD (20) or MSA (21,22). Dementia may occur in patients with late-onset PD (23), PSP (24,25), or CBD (26). It is a major feature of DLB, although there may be fluctuations of intellectual functioning from one day to another (27). Memory Learning disorders in neurodegenerative diseases may be assessed by tools, such as the California Verbal Learning Test (13) or the Grober and Buschke Test (14) that make it possible to analyze specific memory processes and distinguish between storage and retrieval difficulties. The key for understanding the relationship between memory disorders and degenerative diseases implicates the functional mediotemporal vs frontal dissociation. Encoding deficits, loss of information after a delay, low effect of cuing on recall, high number of extralist intrusions, and false positives in recog-

3 Added Value of the Neuropsychological Evaluation 187 nition characterize diseases associated with lesion of hippocampal and perihippocampal areas such as Alzheimer s disease (AD) (28). By contrast, predominant retrieval deficits, manifested by the opposition between impaired free recall and correct cued recall and recognition, are present in diseases associated with dysfunction of striatofrontal neuronal circuits such as PSP or PD with dementia (PDD) (29). Milder deficient activation of the frontal component of memory processes occurs in PD (30,31), MSA (22), and CBD (32,33). Little has been published on learning disorders in DLB, but a study with autopsy-confirmed cases show that they are less severe than in AD (34). Clinical evidence suggests that although cued recall is less efficient in DLB than in PD or PSP, it is better preserved than in AD. A similar contrast between a true loss of information in AD and retrieval deficits in PDD also applies to retrograde amnesia. Instrumental Activities Instrumental dysfunction, suggestive of temporoparietal lesions, include aphasia, apraxia, and visuospatial deficits. Aphasia and apraxia may be investigated by clinical batteries, such as the Boston Diagnostic Aphasia Examination (15) or the Heilman and Gonzalez Rothi battery for apraxia (16). Visuospatial deficits are less clearly defined and do not allow the differential diagnosis of the different diseases, since various cognitive abilities, such as visuospatial perception, drawing, or constructive aptitude, and conceptual thinking may affect performance (35). Impairment of instrumental activities is specific to neurodegenerative diseases with a cortical involvement. Aphasia may be observed in DLB (27), whereas apraxia is more characteristic of CBD (32,36). In contrast, instrumental functions are mildly disturbed in PSP (37) and PDD (38) and are preserved in PD (39) and MSA (22). Executive Functions Executive functions, namely the mental processes involved in behavioral planning, particularly when the environment requires adaptation to a new situation, are under the control of striatofrontal circuits. These functions may be investigated at the patient s bedside (6) (see video) or by a neuropsychological evaluation assessing the main processes mediated by striatofrontal loops such as set elaboration, set maintenance, and set shifting, inhibition of interferences, motor programming, and environmental autonomy (Table 1). These functions are impaired at an early stage of all parkinsonian disorders, but are much less severe in PD and MSA than in the other parkinsonian syndromes (25,40). Behavioral Disorders Delusions and hallucinations, as diagnosed in accordance with the DSM IV criteria (18), are common at early stages of DLB (27). They occur in PD, particularly in demented patients or as a result of treatment with anticholinergic or dopaminergic drugs, but are not characteristic of MSA, PSP, or CBD (41). Apathy and disinhibition may also be observed in parkinsonian disorders (42). Apathy has been defined as a lack of motivation and responsiveness to both positive and negative events in the absence of emotional distress or negative thoughts. It can be distinguished from depression using new scales, such as the Neuropsychiatric Inventory (17). Apathy is particularly frequent in PSP (43) and DLB (44), whereas irritability predominates in CBD (45) and depression in PD (44) (see Chapter 11). WHICH NEUROPSYCHOLOGICAL PATTERN CHARACTERIZES EACH OF THE MAIN PARKINSONIAN DISORDERS? Well-characterized neuropsychological profiles can be drawn from the clustering of the cognitive and behavioral characteristics found in each parkinsonian disorder (Table 2). The absence of marked cognitive or behavioral changes makes more probable the diagnosis of PD or MSA, whereas a severe dysexecutive syndrome suggestive of a striatofrontal dysfunction reinforces the diagnosis of PSP and specific deficits related to a cortical involvement contribute to the diagnosis of CBD or DLB.

4 188 Dubois and Pillon Table 2 Neuropsychological Pattern of Each Disease PD MSA PSP PDD CBD DLB Dementia Mattis DRS (144) >130 >130 <130 <130 <130 <130 Fluctuations Dysexecutive syndrome FAB (18) Envt Dependency ± ± ++ + ± + Memory deficits Free recall (48) Total recall (48) Instrumental deficits Language - - ± ± + + Gesture - - ± ± ++ ± Psychosis Mean indicative values adapted from refs. 6, 22, 29, 32, 52. -, absent; ±, mild or discussed; +, moderate or present in a proportion of patients; ++, severe and present in a majority of patients. Parkinson s Disease Cognitive changes in the majority of patients with PD are subtle and mainly restricted to attentional and retrieval deficits. It is only by using appropriate neuropsychological tests that these cognitive changes can be detected. They mainly concern (a) the visuospatial domain, observed in visuospatial paradigms that require self-elaboration of the response or forward-planning capacity; (b) memory, that is, working memory and long-term memory, especially in tasks that involve self-organization of the to-be-remembered material, temporal ordering and conditional associative learning, and procedural learning; and (c) executive functions, namely concept formation and problem solving, setmaintenance and set-shifting (for a review, see ref. 46). Mood and behavioral changes are also described in PD. Depression is encountered in about 30% of patients and has been the focus of a large number of studies (47). It is important to diagnose it because depression induces attention and memory disorders and, if sufficiently severe, impairs cognitive functions especially those of the executive system in relation to a significant decrease in frontal metabolism evidenced on positron emission tomography (PET) scan studies. More recently, attention has been drawn to apathy and its relation to basal ganglia disorders. Apathy is not infrequent in PD and has repercussions on cognitive functions, affect, and behavior (48,49). Unlike depression, anxiety symptoms almost always begin after the onset of the motor symptoms and are related to medication-induced on off fluctuations and wearing-off condition in most of the cases. Drug-induced psychiatric disorders are frequently found in PD and mainly consist of hallucinations and delusions. These disorders are, however, much more frequent in PDD or DLB (44). To conclude, the clinical diagnosis of PD relies on the evidence of a parkinsonian syndrome responsive to levodopa in the absence of severe intellectual or memory dysfunction. This is the rule, at least, in the young-onset form of the disease. In the late-onset one, however, a subcorticofrontal dementia may occur after several years of evolution, which may result from the compounding effect of diseaserelated neuronal lesions and age-related neuronal changes (50). PDD is characterized by a marked dysexecutive syndrome, accompanied by a severe amnesic syndrome with a persistent response to cuing, in the absence of true aphasia, apraxia, or agnosia, and may be difficult to diagnose. DSM IV criteria of dementia (18) are well suited to AD, but less appropriate for PD because the severe motor

5 Added Value of the Neuropsychological Evaluation 189 deficits may themselves affect patient s autonomy. Moreover, an overestimation of the severity of cognitive impairment may result from nonspecific factors (akinesia, hypophonia, depression, anxiety, marked cognitive slowing with delay in responses, uncontrolled dyskinesias) that interfere with the evaluation of cognitive functions. Multiple System Atrophy Cognitive changes are mild in the parkinsonian variant of MSA (MSA-P, previously called striatonigral degeneration), at least in the early stage of the disease, before patients reach a severe akinetic state with dysarthria, which may affect the cognitive evaluation. The few studies of cognition in MSA, including the MSA-P variant, display few differences from the neuropsychological pattern of PD: some more severe deficits in the Stroop test (51) or in verbal fluency (52). In our experience, neuropsychological testing does not help to distinguish between the two disorders. In contrast, when faced to an axial parkinsonian syndrome poorly responsive to levodopa, the absence of a severe subcorticofrontal syndrome strongly favors the diagnosis of MSA-P and decreases the probability for PSP (22,53). Psychiatric disorders have been poorly studied in MSA-P. Depression, anxiety, and emotional lability have been described, but not psychosis (54). Progressive Supranuclear Palsy Cognitive and behavioral changes are consistent even in the early stages of the disease. Cognitive slowing and inertia occur in the first year in 52% of cases. As the disease progresses, these changes progressively worsen. From 24 patients who underwent two or more neuropsychological evaluations over time, 38% showed a global impairment at their first examination, and 70% 15 mo later. The changes may become severe enough to warrant the diagnosis of dementia, but the deficits still conform to the pattern of subcorticofrontal dementia. The dysexecutive syndrome of PSP is much more severe than that observed in any other subcortical disorders, and the memory deficit is dramatically improved in conditions that facilitate retrieval processing such as cueing and recognition. Cognitive slowing appears evident in patients with PSP, who answer questions and solve even the simplest problems with delay. It is a genuine slowing of central-processing time unrelated to motor or affective disorders, as demonstrated experimentally using reaction time tasks (55) and event-related brain potentials (56). Cognitive slowing may contribute to decreased lexical fluency that is more severely impaired in patients with PSP than in patients with PD or AD, although naming is more affected in the latter (25). The deficit is observed in different types of fluency, including semantic fluency, where patients have to list animal names or objects that can be found in a supermarket, phonemic fluency, where patients are required to produce words beginning with a given letter, and design fluency, where patients must produce abstract designs (57). A tendency to perseverate may also account for some of the deficits, particularly in tasks involving concept formation and shifting ability. In the Wisconsin Card Sorting Test, PSP patients complete a smaller number of categories than patients with PD or MSA-P. This lack of flexibility affects both categorical and motor sequencing, as shown by the poor performance of patients with PSP in the Trail Making Test and in the motor series of Luria. Patients with PSP also experience difficulty in conceptualization and problem-solving ability, which may account for their poor performance in similarities, interpretation of proverbs, comprehension of abstract concepts, arithmetic and lineage problems, tower tasks, and picture arrangement. This severe dysexecutive syndrome contributes to the memory deficits and instrumental disorders observed in PSP. Short-term memory was found to be impaired using the Brown Peterson paradigm, a working memory task in which the patients were more sensitive than controls to interference. Longterm memory is also disturbed in PSP, as shown by immediate and delayed recall of the subtests of

6 190 Dubois and Pillon the Wechsler Memory Scale, the Rey Auditory Verbal Learning Test, and the California Verbal Learning Test. However, when encoding is controlled by using semantic category cues and when recall is performed with the same cues, as in the Grober and Buschke procedure, recall performance of the patients dramatically improves, confirming that there is no genuine amnesia in the disease (29). Various speech disorders have been described in PSP. A severe reduction of spontaneous speech resembling dynamic aphasia is usually observed (58), but abnormal loquacity has also been reported. Word-finding difficulty may occur, but it is generally less severe than in AD patients. Semantic or syntactic comprehension disorders are absent or mild. Dynamic apraxia may be found (32). Bilateral apraxic errors for transitive and intransitive movements have been reported, but they are much less severe than in CBD (59). Visual and auditory perception may be disturbed, but there is no evidence of object agnosia or alexia. Therefore, instrumental disorders of patients with PSP, when present, are rather considered to be a consequence of impaired executive and perceptual-motor functions or attentional disorders. Besides cognitive impairment, patients with PSP exhibit behavioral disorders. They show severe difficulty in self-guided behavior and are abnormally dependent on stimuli from the environment. They involuntarily grasp all the objects presented in front of them; they imitate the examiner s gestures passively and use objects in the absence of any explicit verbal orders (25). Such uncontrolled behaviors are never observed in normal control subjects in the absence of explicit demands and are considered to result from a lack of the inhibitory control normally exerted by the frontal lobes (12). PSP patients also have difficulty in inhibiting an automatic motor program once it is initiated. This can easily be evaluated with the signe de l applaudissement [ clapping sign ] (60): when asked to clap their hands three times consecutively, as quickly as possible, these patients have a tendency to clap more (four or five times), sometimes initiating an automatic program of clapping that they are unable to stop, as if they had difficulty in programming voluntary acts that compete with overlearned motor skills. This sign seems to be specific to striatal dysfunction occurring in PSP (61). Changes in mood, emotion, and personality have also been described: most frequently bluntness of affective expression and lack of concern about personal behavior or the behavior of others, but sometimes obsessive disorders or disinhibition with bulimia, inappropriate sexual behavior, or aggressiveness. These changes are difficult to investigate, given the lack of insight and the transient nature of the emotions expressed. The testimony of caregivers is therefore required. Administering the Neuropsychiatric Inventory (NPI) to patients informants showed that patients with PSP exhibited apathy almost as a rule, since it was observed in 91% of the cases (43). Apathy was more frequent in PSP than in any other parkinsonian syndrome. Corticobasal Degeneration The cognitive profile of this disease is distinct from that of PSP, because of the presence of signs suggestive of cortical involvement. Many patients present only limb clumsiness and gesture disorders at the first examination, without any or with few cognitive or behavioral symptoms (26). In contrast, the disease may begin by other signs of cortical involvement, particularly nonfluent progressive aphasia (62). Finally, a severe frontal cognitive and behavioral syndrome may initiate the disease in some patients (63). CBD is typically defined by unilateral rigidity of one arm with apraxic features, accounting for the proposition of the new term progressive asymmetric rigidity and apraxia syndrome (64). Gesture disorders are so characteristic of the disease that the diagnosis can be suspected on the simple analysis of the motor disturbances. They consist, at first, of the patient experiencing difficulty or showing perplexity in the performance of delicate and fine movements of the fingers of one hand. At this stage, patients complain of clumsiness and loss of manual dexterity, reminiscent of limb apraxia, variously described as kinesthetic in patients with lesions of the parietal cortex, or kinetic in

7 Added Value of the Neuropsychological Evaluation 191 patients with lesions of the premotor cortex. Systematic evaluation shows disorders of dynamic motor execution (impaired bimanual coordination, temporal organization, control, and inhibition) (32). Asymmetric praxis disorders (difficulty in posture imitation, symbolic gesture execution, and object utilization) are also regularly observed, even at this stage. Ideomotor apraxia is frequent, especially in patients who have initial symptoms in the right limb, in agreement with the hypothesis of a predominant storage of movement formulae in the left hemisphere (65). In addition, central deficits in action knowledge and mechanical problem solving have been linked to parietal lobe pathology (66). Alien limb phenomenon, in which a limb behaves in an uncooperative or foreign way, has been attributed to lesions affecting the supplementary motor area. Its occurrence, in the absence of a known callosal lesion, would be highly suggestive of the diagnosis of CBD. Other signs of cortical involvement have been observed in CBD. Linguistic disturbances are found, consisting of word-finding difficulties, decreased lexical fluency, transcortical motor aphasia, or progressive phonetic disintegration (67). These deficits resembling primary progressive nonfluent aphasia can even be an initial symptom of CBD. Neglect and visuospatial deficits have also been reported. Constructive apraxia is observed in patients with predominant right-hemisphere lesions, in relation with the well-known influence of this hemisphere on visuospatial function. Other cognitive changes resemble the subcorticofrontal dysfunction of PSP: a dysexecutive syndrome and a learning deficit that can be alleviated by semantic cuing (32). The environmental dependency syndrome, thought to be related to a release of the inhibition normally exerted by the frontal lobes on the activity of the parietal lobes (12), is less frequent, however, in CBD than in PSP, probably because of the parietal lobe dysfunction in this disease. Early subcorticofrontal syndrome in CBD would predict a shorter survival. In most of the clinical studies performed on CBD patients, the level of intellectual deterioration was mild or moderate until an advanced stage of the disease. In some cases, however, patients with a severe dysexecutive syndrome associated with memory disorders and impaired instrumental activities may reach the threshold of dementia in which both cortical and subcorticofrontal components play a role. Thus, dementia is not infrequent in CBD and may even be observed from the onset in unusual clinical presentation. In 10 out of 13 cases with pathologically proven CBD, dementia was noticed within 3 yr of onset of symptoms (68). Besides frontal lobe type behavioral alterations, patients with CBD may present neuropsychiatric disorders. In a series of CBD patients, the NPI showed that depression, apathy, irritability, and agitation were the symptoms most commonly exhibited (45). The depression and irritability of patients with CBD were more frequent and severe than those of patients with PSP, whereas patients with PSP exhibited more apathy. Dementia With Lewy Bodies The diagnosis of DLB can be suspected clinically on the basis of the early occurrence of a cognitive decline resembling a chronic confusional state with fluctuating cognitive signs and visual and/or auditive hallucinations in a patient with mild parkinsonism (69). The rapidly progressive dementia is accompanied by aphasia, dyspraxia, or spatial disorientation, suggestive of temporoparietal dysfunction. The neuropsychological profile differs from that of patients with AD: cognitive deficits are more acute, attentional fluctuations more intense, and psychotic features appear earlier. Moreover, patients with DLB present a more severe dysexecutive impairment but less severe memory deficits than patients with AD (34). The neuropsychological pattern of DLB can also be distinguished from the subcortical dementia of PD on the basis of the early occurrence of cognitive deficits and psychotic features, and the presence of linguistic and visuospatial disorders (44,70). It is, however, controversial whether DLB constitutes a disorder different from or overlapping with PDD. By convention, DLB is only considered when the cognitive changes appear before, with or within 1 yr after the occurrence of parkinsonism and cannot be proposed when they appear several years later (69). At a

8 192 Dubois and Pillon Table 3 Diagnostic Contribution of Motor and Cognitive Deficits Motor Syndrome Cognitive Changes L-dopa React Axial Synd Severity Occurrence Cortical Signs MDP + - ± early - MSA ± + ± early - PDD late - PSP early - DLB ± + + early + CBD - - ± late + -, absent; ±, mild or discussed; +, moderate or present in a proportion of patients; ++, severe and present in a majority of patients. first glance, the clinical and cognitive profiles of both diseases are rather different with cortical signs only in DLB. The profile of attentional impairments and fluctuating attention (71) and the cognitive pattern at the Mattis Dementia Rating Scale (72) would be, however, rather similar in PDD and DLB, and postmortem examination revealed cortical Lewy bodies in both diseases, suggesting that their differential diagnosis may be more difficult than previously thought (73). CONCLUSION Appropriate tests may help to differentiate among diseases associated with parkinsonism (Table 3). Schematically, three categories can be distinguished. The first group is defined by mild cognitive deficits. It includes PD and MSA, which have a similar subcorticofrontal pattern of impairment. In the second group (PSP), striatofrontal dysfunction is so severe that it leads to dramatic planning, monitoring, and recall deficits, evolving toward dementia. The third group of diseases (CBD and DLB) is characterized by signs of cortical involvement with asymmetric instrumental disorders in CBD (praxic and linguistic deficits) and more severe dementia with hallucinations in DLB. The inclusion of PDD in the second or the third category is an object of debate and further studies are required. The neuropsychological profiles described herein are valid when applied to a group of patients with a particular disease. To assess individuals is more difficult. The distribution of the subcortical lesions and the severity of the resulting denervation can vary. The association of cortical lesions with those of the basal ganglia can produce composite pictures. Age at onset and disease duration can alter the neuropsychological picture at different points in time. Nevertheless, appropriate neuropsychological testing is a useful technique for investigating the neuronal pathways affected in these diseases, and can contribute, not only to the diagnosis, but also to our understanding of the underlying pathology. A better clinical knowledge of these diseases will allow the progressive selection and elaboration of shorter and more discriminant tools. Longitudinal studies with pathological confirmation are necessary to attain this aim (see below). RESEARCH TO BE DONE TO AMELIORATE THE NEUROPSYCHOLOGICAL EVALUATION OF ATYPICAL PARKINSONIAN DISORDERS Three directions: Elaboration of diagnostic criteria for subcorticofrontal dementia. Validation of new neuropsychological tools more sensitive to the specific aspects of each disease. Longitudinal evaluation of each disease with the same tools to better evaluate their sensitivity and specificity and postmortem anatomo-pathological correlation when possible.

9 Added Value of the Neuropsychological Evaluation 193 REFERENCES 1. Litvan I, Agid Y, Calne D, et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele Richardson Olszewski syndrome): Report of the NINDS-SPSP International Workshop. Neurology 1996;47: Litvan I, Agid Y, Goetz C, et al. Accuracy of clinical diagnosis of corticobasal degeneration. Neurology 1997;48: Hughes AJ, Daniel SE, Kilford L, Lees AJ. The accuracy of clinical diagnosis of idiopathic Parkinson s disease: a clinicopathological study. J Neurol Neurosurg Psychiatry 1992;55: Troster AI, Woods SP, Fields JA, et al. Neuropsychological deficits in essential tremor: an expression of cerebellothalamo-cortical pathophysiology? Eur J Neurol 2002;9: Mattis S. Dementia Rating Scale. Odessa, FL: Psychological Assessment Resources Inc., Dubois B, Slachevsky A, Litvan I, Pillon B. The FAB: a Frontal Assessment Battery at bedside. Neurology 2000;55: Nelson HE. A modified Card Sorting Test sensitive to frontal lobe defect. Cortex 1976;12: Benton AL. Differential behavioral effects in frontal lobe disease. Neuropsychologia 1968;6: Reitan RM. Validity of the Trail Making Test as an indication of organic brain damage. Percept Mot Skills 1958;8: Golden CJ. Stroop Color and Word Test. Chicago: Stoelting Company, Luria AR. Higher Cortical Functions in Man. New York, NY: Basic Books, Lhermitte F, Pillon B, Serdaru M. Human autonomy and the frontal lobes, I: imitation and utilization behaviors: a neuropsychological study of 75 patients. Ann Neurol 1986;19: Delis DC, Kramer JH, Kaplan E, Ober BA. California Verbal Learning Test: Research Edition. New York: Psychological Corporation, Grober E, Buschke H. Genuine memory deficits in dementia. Dev Neuropsychol 1987;3: Goodglass H, Kaplan E. The Assessment of Aphasia and Related Disorders. Philadelphia: Lea & Febiger, Heilman KM, Gonzalez Rothi LJ. Apraxia. In: Heilman KM, Valenstein E, eds. Clinical Neuropsychology, 2nd ed. Oxford: Oxford University Press, 1985: Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994;44: American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Washington, DC: American Psychiatric Association, Quinn N, Critchley P, Marsden CD. Young onset Parkinson s disease. Mov Disord 1987; 2: Cooper JA, Sagar HJ, Jordan N, Harvey NS, Sullivan EV. Cognitive impairment in early untreated Parkinson s disease and its relationship to motor disability. Brain 1991;114: Robbins TW, James M, Lange KW, Owen AM, Quinn NA, Marsden CD. Cognitive performance in Multiple System Atrophy. Brain 1992;115: Pillon B, Gouider-Khouja N, Deweer B, et al. Neuropsychological pattern of striatonigral degeneration: comparison with Parkinson s disease and progressive supranuclear palsy. J Neurol Neurosurg Psychiatry 1995;58: Zetusky WJ, Jankovic J, Pirozzolo FJ. The heterogeneity of Parkinson s disease: clinical and prognostic implications. Neurology 1985;35: Maher ER, Lees AJ. The clinical features and natural history of the Steele Richardson Olszewski syndrome (progressive supranuclear palsy). Neurology 1986;36: Pillon B, Dubois B, Ploska A, Agid Y. Severity and specificity of cognitive impairment in Alzheimer s, Huntington s, and Parkinson s diseases and progressive supranuclear palsy. Neurology 1991;41: Wenning GK, Litvan I, Jankovic J, et al. Natural history and survival of 14 patients with corticobasal degeneration confirmed at postmortem examination. J Neurol Neurosurg Psychiatry 1998;64: Byrne EJ, Lennox G, Lowe J, Godwin-Austen RB. Diffuse Lewy body disease: clinical features in 15 cases. J Neurol Neurosurg Psychiatry 1989;52: Tounsi H, Deweer B, Ergis AM, et al. Sensitivity to semantic cuing: An index of episodic memory dysfunction in early Alzheimer s disease. Alzheimer disease and associated disorders 1999;13: Pillon B, Deweer B, Michon A, Malpand C, Agid Y, Dubois B. Are explicit memory disorders of progressive supranuclear palsy related to damage to striatofrontal circuits? Comparison with Alzheimer s, Parkinson s, and Huntington s diseases. Neurology 1994;44: Taylor AE, Saint-Cyr JA, Lang AE. Memory and learning in early Parkinson s disease: evidence for a frontal lobe syndrome. Brain Cogn 1990;13: Buytenhuijs EJ, Berger JC, van Spaendonck KP, Horstink MW, Borm GF, Cools AR. Memory and learning strategies in patients with Parkinson s disease. Neuropsychologia 1994;32: Pillon B, Blin J, Vidailhet M, et al. The neuropsychological pattern of corticobasal degeneration. Comparison with progressive supranuclear palsy and Alzheimer s disease. Neurology 1995; 45: Massman PJ, Kreiter KT, Jankovic J, Doody RS. Neuropsychological functioning in cortical-basal ganglionic degeneration: differenciation from Alzheimer s disease. Neurology 1996;46:

10 194 Dubois and Pillon 34. Connor DJ, Salmon DP, Sandy TJ, Galasko D, Hansen LA, Thal L. Cognitive profiles of autopsy-confirmed Lewy body variant vs pure Alzheimer s disease. Arch Neurol 1998; 55: Brown RG, Marsden CD. Subcortical dementia : the neuropsychological evidence. Neurosci 1988;25: Leiguarda R, Merello M, Nouzeilles MI, Balej J, Rivero A, Nagues M. Limb-kinetic apraxia in corticobasal degeneration: clinical and kinematic features. Mov Disord 2003;18: Maher ER, Smith EM, Lees AJ. Cognitive deficits in the Steele Richardson Olszewski syndrome (progressive supranuclear palsy). J Neurol Neurosurg Psychiatry 1985;48: Ross GW, Mahler ME, Cummings JL. The dementia syndromes of Parkinson s disease: cortical and subcortical features. In: Huber SJ, Cummings JL, eds. Parkinson s Disease: Neurobehavioral Aspects. Oxford: Oxford University Press,1992: Taylor AE, Saint-Cyr JA, Lang AE. Frontal lobe dysfunction in Parkinson s disease. Brain 1986;109: Owen AM, Robbins TW. Comparative neuropsychology of Parkinsonian syndromes. In: Wolters EC, Scheltens P, eds. Mental Dysfunction in Parkinson s Disease. Proceedings of the European Congress on Mental Dysfunction in Parkinson s Disease held in Amsterdam on October Amsterdam: Vrije Universiteit, 1993: Cummings JL. Psychosis in basal ganglia disorders. In: E Wolters E, Scheltens P, eds. Mental Dysfunction in Parkinson s Disease. Proceedings of the European Congress on Mental Dysfunction in Parkinson s Disease held in Amsterdam on October Amsterdam: Vrije Universiteit, 1993: Litvan I, Paulsen JS, Mega MS, Cummings JL. Neuropsychiatric assessment of patients with hyperkinetic and hypokinetic movement disorders. Arch Neurol 1998;55: Litvan I, Mega MS, Cummings JL, Fairbanks L. Neuropsychiatric aspects of progressive supranuclear palsy. Neurology 1996;47: Aarsland D, Ballard G, Larsen JP, McKeith I. A comparative study of psychiatric symptoms in dementia with diffuse Lewy body disease and Parkinson s disease with and without dementia. Int J Geriatr Psychiatry 2001;16: Cummings JL, Litvan I. Neuropsychiatric aspects of corticobasal degeneration. In: Litvan I, Goetz CG, Lang AE, eds. Corticobasal Degeneration. Advances in Neurology, vol. 82. Philadelphia: Lippincott, Williams & Wilkins, 2000: Pillon B, Boller F, Levy R, Dubois B. Cognitive deficits and dementia in Parkinson s disease. In: Boller F, Grafman J (eds.). Handbook of Neuropsychology, vol 6. Aging and Dementia. Amsterdam: Elsevier, 2001: Slaughter JR, Slaughter KA, Nichols D, Holmes SE, Martens MP. Prevalence, clinical manifestations, etiology, and treatment of depression in Parkinson s disease. J Neuropsychiatry Clin Neurosci 2001;13: Pluck GC, Brown RG. Apathy in Parkinson s disease. J Neurol Neurosurg Psychiatry 2002;73: Czernecki V, Pillon B, Houeto JL, Pachon JB, Levy R, Dubois B. Motivation, reward, and Parkinson s disease: influence of dopatherapy. Neuropsychologia 2002;40: Katzen HL, Levin BE, Llabre ML. Age of disease onset influences cognition in Parkinson s disease. J Int Neuropsychol Soc 1998;4: Meco G, Gasparini M, Doricchi F. Attentional functions in multiple system atrophy and Parkinson s disease. J Neurol Neurosurg Psychiatry 1996;60: Soliveri P, Monza D, Paridi D, et al. Neuropsychological follow-up in patients with Parkinson s disease, striatonigral degeneration-type multisystem atrophy, and progressive supranuclear palsy. J Neurol Neurosurg Psychiatry 2000;69: Brown RG, Pillon B, Uttner I, and Members of the Neuropsychology Working Group and NNIPPS Consortium, France, Germany, UK. Cognitive function in patients with progressive supranuclear palsy and multiple system atrophy. The Movement Disorder Society, 7th International Congress of Parkinson s disease and Movement Disorders, November Book of Abstracts, 2002, P Ghika J. Mood and behavior in disorders of the basal ganglia. In: Bogousslavsky J, Cummings JL, eds. Behavior and Mood Disorders in Focal Brain Lesions. Cambridge: Cambridge University Press, 2000: Dubois B, Pillon B, Legault F, Ajid Y, Lhermitte F. Slowing of cognitive processing in progressive supranuclear palsy. A comparison with Parkinson s disease. Arch Neurol 1988;45: Johnson R. Event-related brain potentials. In: Litvan I, Agid Y, eds. Progressive Supranuclear Palsy. Oxford: Oxford University Press, 1992: Grafman J, Litvan I, Stark M. Neuropsychological features of progressive supranuclear palsy. Brain Cogn 1995;28: Esmonde T, Giles E, Xuereb J, Hodges J. Progressive supranuclear palsy presenting with dynamic aphasia. J Neurol Neurosurg Psychiatry 1996;60: Pharr V, Uttl B, Stark M, Litvan I, Fantie B, Grafman J. Comparison of apraxia in corticobasal degeneration and progressive supranuclear palsy. Neurology 2001;56: Dubois B, Défontaines B, Deweer B, Malapani C, Pillon B. Cognitive and behavioral changes in patients with focal lesions of the basal ganglia. In: Weiner WJ, Lang AE, eds. Behavioral Neurology of Movement Disorders. Advances in Neurology, vol. 65. New York: Raven, 1995:

11 Added Value of the Neuropsychological Evaluation Slachevsky A, Pillon B, Beato R, et al. The Signe de l Applaudissement in PSP. American Academy of Neurology 54th Annual Meeting, Denver, April 13 20, Neurology 2002;58(Suppl 3):P Kertez A, Martinez-Lage P, Davidson W, Munoz DJ. The corticobasal degeneration syndrome overlaps progressive aphasia and frontotemporal dementia. Neurology 2000;55: Bergeron C, Davis A, Lang AE. Corticobasal ganglionic degeneration and progressive supranuclear palsy presenting with cognitive decline. Brain Pathology 1998;8: Lang AE, Maragonore D, Marsden CD, et al. Movement Disorder Society Symposium on cortico-basal ganglionic degeneration (CBGD) and its relationship to other asymmetrical cortical degeneration syndromes. Mov Disord 1996;11: Leiguarda R, Lees AJ, Merello M, Starkstein S, Marsden CD. The nature of apraxia in corticobasal degeneration. J Neurol Neurosurg Psychiatry 1994;57: Spatt J, Bak T, Bozeat S, Patterson K, Hodges JR. Apraxia, mechanical problem solving and semantic knowledge: contributions to object usage in corticobasal degeneration. J Neurol 2002;249: Frattali CM, Grafman J, Patronas N, Makhlouf MS, Litvan I. Language disturbances in corticobasal degeneration. Neurology 2000;54: Grimes DA, Lang AE, Bergeron C. Dementia is the most common presentation of corticobasal ganglionic degeneration. Neurology 1999;53: Barber R, Panikkar A, McKeith IG. Dementia with Lewy bodies: diagnosis and management. Int J Geriatr Psychiatry 2001;16(Suppl 1): Gnanalingham K, Byrne E, Thornton A, Samabrook MA, Bannister P. Motor and cognitive function in Lewy body dementia: comparison with Alzheimer s and Parkinson s disease. J Neurol Neurosurg Psychiatry 1997;62: Ballard CG, Aarsland D, McKeith I, et al. Fluctuations in attention: PD dementia vs DLB with parkinsonism. Neurology 2002;59: Aarsland D, Litvan I, Salmon D, Galasko D, Wentzel-larsen T, Larsen JP. Performance on the dementia rating scale in Parkinson s disease with dementia and dementia with Lewy bodies: comparison with progressive supranuclear palsy and Alzheimer s disease. J Neurol Neurosurg Psychiatry 2003;74: Apaydin H, Ahlskog JE, Parisi JE, Boeve BF, Dickson DW. Parkinson disease neuropathology: later-developing dementia and loss of the levodopa response. Arch Neurol 2002;59:

12

Original Articles. Calne, resting tremor. Mortimer, Pirozzolo, Hansch, & Webster, postural disturbance III

Original Articles. Calne, resting tremor. Mortimer, Pirozzolo, Hansch, & Webster, postural disturbance III 2004 97-106 Original Articles 1 2 3 1 1 2 3 47 22 III I II muscular rigidity postural disturbance resting tremor bradykinesia Calne, 2001 Mortimer, Pirozzolo, Hansch, & Webster, 1982 Tel: 02-23627076 E-mail:

More information

Neuropsychological pattern of striatonigral

Neuropsychological pattern of striatonigral 174 17ournal of Neurology, Neurosurgery, and Psychiatry 1 995;58: 174-179 INSERM U 289 and Federation de Neurologie, Hopital de la Salpetriere, 47 Boulevard de l'hopital, 75651 Paris cedex 13, France B

More information

Nature, prevalence and clinical significance. Barcelona, Spain

Nature, prevalence and clinical significance. Barcelona, Spain Nature, prevalence and clinical significance Jaime Kulisevsky Barcelona, Spain 1 Non motor (neuropsychiatric) symptoms are an integral part of Parkinson s s disease (PD) Affective disorders And are associated

More information

Clinical Diagnosis. Step 1: Dementia or not? Diagnostic criteria for dementia (DSM-IV)

Clinical Diagnosis. Step 1: Dementia or not? Diagnostic criteria for dementia (DSM-IV) Step 1: Dementia or not? Diagnostic criteria for dementia (DSM-IV) A. The development of multiple cognitive deficits manifested by both 1 and 2 1 1. Memory impairment 2. One (or more) of the following

More information

Objectives. RAIN Difficult Diagnosis 2014: A 75 year old woman with falls. Case History: First visit. Case History: First Visit

Objectives. RAIN Difficult Diagnosis 2014: A 75 year old woman with falls. Case History: First visit. Case History: First Visit Objectives RAIN Difficult Diagnosis 2014: A 75 year old woman with falls Alexandra Nelson MD, PhD UCSF Memory and Aging Center/Gladstone Institute of Neurological Disease Recognize important clinical features

More information

Non Alzheimer Dementias

Non Alzheimer Dementias Non Alzheimer Dementias Randolph B Schiffer Department of Neuropsychiatry and Behavioral Science Texas Tech University Health Sciences Center 9/11/2007 Statement of Financial Disclosure Randolph B Schiffer,,

More information

Parkinsonian Disorders with Dementia

Parkinsonian Disorders with Dementia Parkinsonian Disorders with Dementia George Tadros Consultant in Old Age Liaison Psychiatry, RAID, Heartlands Hospital Professor of Dementia and Liaison Psychiatry, Aston Medical School Aston University

More information

Dementia Update. October 1, 2013 Dylan Wint, M.D. Cleveland Clinic Lou Ruvo Center for Brain Health Las Vegas, Nevada

Dementia Update. October 1, 2013 Dylan Wint, M.D. Cleveland Clinic Lou Ruvo Center for Brain Health Las Vegas, Nevada Dementia Update October 1, 2013 Dylan Wint, M.D. Cleveland Clinic Lou Ruvo Center for Brain Health Las Vegas, Nevada Outline New concepts in Alzheimer disease Biomarkers and in vivo diagnosis Future trends

More information

Differential Diagnosis of Hypokinetic Movement Disorders

Differential Diagnosis of Hypokinetic Movement Disorders Differential Diagnosis of Hypokinetic Movement Disorders Dr Donald Grosset Consultant Neurologist - Honorary Professor Institute of Neurological Sciences - Glasgow University Hypokinetic Parkinson's Disease

More information

FTD basics! Etienne de Villers-Sidani, MD!

FTD basics! Etienne de Villers-Sidani, MD! FTD basics! Etienne de Villers-Sidani, MD! Frontotemporal lobar degeneration (FTLD) comprises 3 clinical syndromes! Frontotemporal dementia (behavioral variant FTD)! Semantic dementia (temporal variant

More information

NEUROPSYCHOMETRIC TESTS

NEUROPSYCHOMETRIC TESTS NEUROPSYCHOMETRIC TESTS CAMCOG It is the Cognitive section of Cambridge Examination for Mental Disorders of the Elderly (CAMDEX) The measure assesses orientation, language, memory, praxis, attention, abstract

More information

Common Forms of Dementia Handout Package

Common Forms of Dementia Handout Package Common Forms of Dementia Handout Package Common Forms of Dementia 1 Learning Objectives As a result of working through this module, you should be better able to: 1. Describe clinical features of 4 major

More information

Parkinson Disease. Lorraine Kalia, MD, PhD, FRCPC. Presented by: Ontario s Geriatric Steering Committee

Parkinson Disease. Lorraine Kalia, MD, PhD, FRCPC. Presented by: Ontario s Geriatric Steering Committee Parkinson Disease Lorraine Kalia, MD, PhD, FRCPC Key Learnings Parkinson Disease (L. Kalia) Key Learnings Parkinson disease is the most common but not the only cause of parkinsonism Parkinson disease is

More information

Range of neuropsychiatric disturbances in patients with Parkinson s disease

Range of neuropsychiatric disturbances in patients with Parkinson s disease 492 Section of Geriatric Psychiatry, Rogaland Psychiatric Hospital D Aarsland N G Lim C Janvin Department of Neurology, Central Hospital of Rogaland, Stavanger, Norway J P Larsen K Karlsen E Tandberg Departments

More information

III./3.1. Movement disorders with akinetic rigid symptoms

III./3.1. Movement disorders with akinetic rigid symptoms III./3.1. Movement disorders with akinetic rigid symptoms III./3.1.1. Parkinson s disease Parkinson s disease (PD) is the second most common neurodegenerative disorder worldwide after Alzheimer s disease.

More information

Pharmacologyonline 3: (2010)

Pharmacologyonline 3: (2010) PERSEVERATIONS IN ALZHEIMER DISEASE: ANALYSIS OF THE DISTURBANCE AND POSSIBLE CORRELATIONS M. D Antonio¹, L. Trojano², M. R. De Riso², D. Grossi ² and A. M. Fasanaro¹, ¹Alzheimer Unit, Neurology Department,

More information

Neuropsychiatric features of corticobasal degeneration

Neuropsychiatric features of corticobasal degeneration J Neurol Neurosurg Psychiatry 1998;65:717 721 717 Neuropharmacology Unit, Defense and Veteran Head Injury Program, Jackson Foundation and the Medical Neurology Branch I Litvan National Institutes of Neurological

More information

Cognitive-Motor Interference in Persons with Parkinson Disease

Cognitive-Motor Interference in Persons with Parkinson Disease Cognitive-Motor Interference in Persons with Parkinson Disease Tara L. McIsaac, PhD, PT Associate Professor of Physical Therapy A.T. Still University Arizona School of Health Sciences October 11, 2014

More information

Neuropsychiatric Symptoms of Patients With Progressive Supranuclear Palsy and Parkinson s Disease

Neuropsychiatric Symptoms of Patients With Progressive Supranuclear Palsy and Parkinson s Disease Neuropsychiatric Symptoms of Patients With Progressive Supranuclear Palsy and Parkinson s Disease Dag Aarsland, M.D., Ph.D. Irene Litvan, M.D. Jan P. Larsen, M.D., Ph.D. Neuropsychiatric symptoms are common

More information

Screening and Management of Behavioral and Psychiatric Symptoms Associated with Dementia

Screening and Management of Behavioral and Psychiatric Symptoms Associated with Dementia Screening and Management of Behavioral and Psychiatric Symptoms Associated with Dementia Measure Description Percentage of patients with dementia for whom there was a documented screening* for behavioral

More information

I do not have any disclosures

I do not have any disclosures Alzheimer s Disease: Update on Research, Treatment & Care Clinicopathological Classifications of FTD and Related Disorders Keith A. Josephs, MST, MD, MS Associate Professor & Consultant of Neurology Mayo

More information

2016 Programs & Information

2016 Programs & Information Mayo Alzheimer s Disease Research Clinic Education Center 2016 Programs & Information BROCHURE TITLE FLUSH RIGHT for Persons & Families impacted by Mild Cognitive Impairment Alzheimer s Disease Dementia

More information

The Spectrum of Lewy Body Disease: Dementia with Lewy Bodies and Parkinson's Disease Dementia

The Spectrum of Lewy Body Disease: Dementia with Lewy Bodies and Parkinson's Disease Dementia Disclosures Research support, Parkinson Society Canada, Canadian Institutes of Health Research, Ministry of Economic Development and Innovation, Teva Novartis clinical trial, Principal Investigator CME

More information

DEMENTIA and BPSD in PARKINSON'S DISEASE. DR. T. JOHNSON. NOVEMBER 2017.

DEMENTIA and BPSD in PARKINSON'S DISEASE. DR. T. JOHNSON. NOVEMBER 2017. DEMENTIA and BPSD in PARKINSON'S DISEASE. DR. T. JOHNSON. NOVEMBER 2017. Introduction. Parkinson's disease (PD) has been considered largely as a motor disorder. It has been increasingly recognized that

More information

CHAPTER 5 NEUROPSYCHOLOGICAL PROFILE OF ALZHEIMER S DISEASE

CHAPTER 5 NEUROPSYCHOLOGICAL PROFILE OF ALZHEIMER S DISEASE CHAPTER 5 NEUROPSYCHOLOGICAL PROFILE OF ALZHEIMER S DISEASE 5.1 GENERAL BACKGROUND Neuropsychological assessment plays a crucial role in the assessment of cognitive decline in older age. In India, there

More information

DEMENTIA 101: WHAT IS HAPPENING IN THE BRAIN? Philip L. Rambo, PhD

DEMENTIA 101: WHAT IS HAPPENING IN THE BRAIN? Philip L. Rambo, PhD DEMENTIA 101: WHAT IS HAPPENING IN THE BRAIN? Philip L. Rambo, PhD OBJECTIVES Terminology/Dementia Basics Most Common Types Defining features Neuro-anatomical/pathological underpinnings Neuro-cognitive

More information

The ABCs of Dementia Diagnosis

The ABCs of Dementia Diagnosis The ABCs of Dementia Diagnosis Dr. Robin Heinrichs, Ph.D., ABPP Board Certified Clinical Neuropsychologist Associate Professor, Psychiatry & Behavioral Sciences Director of Neuropsychology Training What

More information

Neuropsychological Evaluation of

Neuropsychological Evaluation of Neuropsychological Evaluation of Alzheimer s Disease Joanne M. Hamilton, Ph.D. Shiley-Marcos Alzheimer s Disease Research Center Department of Neurosciences University of California, San Diego Establish

More information

Introduction to the diagnosis of dementia

Introduction to the diagnosis of dementia Introduction to the diagnosis of dementia Serge Gauthier and Pedro Rosa-Neto This chapter will outline general strategies to establish the presence and the differential diagnosis of dementia, and the case

More information

7/3/2013 ABNORMAL PSYCHOLOGY SEVENTH EDITION CHAPTER FOURTEEN CHAPTER OUTLINE. Dementia, Delirium, and Amnestic Disorders. Oltmanns and Emery

7/3/2013 ABNORMAL PSYCHOLOGY SEVENTH EDITION CHAPTER FOURTEEN CHAPTER OUTLINE. Dementia, Delirium, and Amnestic Disorders. Oltmanns and Emery ABNORMAL PSYCHOLOGY SEVENTH EDITION Oltmanns and Emery PowerPoint Presentations Prepared by: Ashlea R. Smith, Ph.D. This multimedia and its contents are protected under copyright law. The following are

More information

Clinical Differences Among Four Common Dementia Syndromes. a program of Morningside Ministries

Clinical Differences Among Four Common Dementia Syndromes. a program of Morningside Ministries Clinical Differences Among Four Common Dementia Syndromes a program of Morningside Ministries Introduction Four clinical dementia syndromes account for 90% of all cases after excluding reversible causes

More information

Screening for Cognitive Dysfunction in Corticobasal Syndrome: Utility of Addenbrooke s Cognitive Examination

Screening for Cognitive Dysfunction in Corticobasal Syndrome: Utility of Addenbrooke s Cognitive Examination Original Research Article DOI: 10.1159/000327169 Accepted: March 8, 2011 Published online: April 8, 2011 Screening for Cognitive Dysfunction in Corticobasal Syndrome: Utility of Addenbrooke s Cognitive

More information

DIFFERENTIAL DIAGNOSIS SARAH MARRINAN

DIFFERENTIAL DIAGNOSIS SARAH MARRINAN Parkinson s Academy Registrar Masterclass Sheffield DIFFERENTIAL DIAGNOSIS SARAH MARRINAN 17 th September 2014 Objectives Importance of age in diagnosis Diagnostic challenges Brain Bank criteria Differential

More information

Revised criteria for the clinical diagnosis of dementia with Lewy. Dementia with Lewy bodies. (Dementia with Lewy Bodies)

Revised criteria for the clinical diagnosis of dementia with Lewy. Dementia with Lewy bodies. (Dementia with Lewy Bodies) Dementia with Lewy bodies First described: Okazaki H, 1961, Diffuse intracytoplasmic ganglionic inclusions (Lewy type) associated with progressive dementia and quadriparesis in flexion. J Neuropathol Exp

More information

The Person: Dementia Basics

The Person: Dementia Basics The Person: Dementia Basics Objectives 1. Discuss how expected age related changes in the brain might affect an individual's cognition and functioning 2. Discuss how changes in the brain due to Alzheimer

More information

The Frontal Lobes. Anatomy of the Frontal Lobes. Anatomy of the Frontal Lobes 3/2/2011. Portrait: Losing Frontal-Lobe Functions. Readings: KW Ch.

The Frontal Lobes. Anatomy of the Frontal Lobes. Anatomy of the Frontal Lobes 3/2/2011. Portrait: Losing Frontal-Lobe Functions. Readings: KW Ch. The Frontal Lobes Readings: KW Ch. 16 Portrait: Losing Frontal-Lobe Functions E.L. Highly organized college professor Became disorganized, showed little emotion, and began to miss deadlines Scores on intelligence

More information

Carmen Inoa Vazquez, Ph.D., ABPP Clinical Professor NYU School of Medicine Lead Litigation Conference Philadelphia May 19, 2009 Presentation

Carmen Inoa Vazquez, Ph.D., ABPP Clinical Professor NYU School of Medicine Lead Litigation Conference Philadelphia May 19, 2009 Presentation Carmen Inoa Vazquez, Ph.D., ABPP Clinical Professor NYU School of Medicine Lead Litigation Conference Philadelphia May 19, 2009 Presentation Neuropsychological Tests Battery The following List represents

More information

Cognitive and Behavioural Changes After Deep Brain Stimulation of the Subthalamic Nucleus in Parkinson s Disease

Cognitive and Behavioural Changes After Deep Brain Stimulation of the Subthalamic Nucleus in Parkinson s Disease 17 Cognitive and Behavioural Changes After Deep Brain Stimulation of the Subthalamic Nucleus in Parkinson s Disease Antonio Daniele, Pietro Spinelli and Chiara Piccininni Istituto di Neurologia, Università

More information

The FAB. A frontal assessment battery at bedside. B. Dubois, MD; A. Slachevsky, MD; I. Litvan, MD; and B. Pillon, PhD

The FAB. A frontal assessment battery at bedside. B. Dubois, MD; A. Slachevsky, MD; I. Litvan, MD; and B. Pillon, PhD The FAB A frontal assessment battery at bedside B. Dubois, MD; A. Slachevsky, MD; I. Litvan, MD; and B. Pillon, PhD Article abstract Objective: To devise a short bedside cognitive and behavioral battery

More information

ORIGINAL CONTRIBUTION. Cognitive Dysfunction and Impaired Organization of Complex Motility in Degenerative Parkinsonian Syndromes

ORIGINAL CONTRIBUTION. Cognitive Dysfunction and Impaired Organization of Complex Motility in Degenerative Parkinsonian Syndromes ORIGINAL CONTRIBUTION Cognitive Dysfunction and Impaired Organization of Complex Motility in Degenerative Parkinsonian Syndromes D. Monza, MD; P. Soliveri, MD; D. Radice, PhD; V. Fetoni, MD; D. Testa,

More information

SECTION 1: as each other, or as me. THE BRAIN AND DEMENTIA. C. Boden *

SECTION 1: as each other, or as me. THE BRAIN AND DEMENTIA. C. Boden * I read all the available books by other [people with] Alzheimer s disease but they never had quite the same problems as each other, or as me. I t s not like other diseases, where there is a standard set

More information

Executive function and behaviour

Executive function and behaviour 3 rd Congress of the European Academy of Neurology Amsterdam, The Netherlands, June 24 27, 2017 Teaching Course 16 Higher cortical function in neurology - an update - Level 2 Executive function and behaviour

More information

Erin Cullnan Research Assistant, University of Illinois at Chicago

Erin Cullnan Research Assistant, University of Illinois at Chicago Dr. Moises Gaviria Distinguished Professor of Psychiatry, University of Illinois at Chicago Director of Consultation Liaison Service, Advocate Christ Medical Center Director of the Older Adult Program,

More information

Clinical Features and Treatment of Parkinson s Disease

Clinical Features and Treatment of Parkinson s Disease Clinical Features and Treatment of Parkinson s Disease Richard Camicioli, MD, FRCPC Cognitive and Movement Disorders Department of Medicine University of Alberta 1 Objectives To review the diagnosis and

More information

Verbal and visual memory in patients with early Parkinson s disease: Effect of levodopa

Verbal and visual memory in patients with early Parkinson s disease: Effect of levodopa Original Article Verbal and visual memory in patients with early Parkinson s disease: Effect of levodopa Sumit Singh, Madhuri Behari Department of Neurology, All India Institute of Medical Sciences, Ansari

More information

FDG-PET e parkinsonismi

FDG-PET e parkinsonismi Parkinsonismi FDG-PET e parkinsonismi Valentina Berti Dipartimento di Scienze Biomediche, Sperimentali e Cliniche Sez. Medicina Nucleare Università degli Studi di Firenze History 140 PubMed: FDG AND parkinsonism

More information

What if it s not Alzheimer s? Update on Lewy body dementia and frontotemporal dementia

What if it s not Alzheimer s? Update on Lewy body dementia and frontotemporal dementia What if it s not Alzheimer s? Update on Lewy body dementia and frontotemporal dementia Dementia: broad term for any acquired brain condition impairing mental function such that ADLs are impaired. Includes:

More information

Prof Tim Anderson. Neurologist University of Otago Christchurch

Prof Tim Anderson. Neurologist University of Otago Christchurch Prof Tim Anderson Neurologist University of Otago Christchurch Tim Anderson Christchurch Insidious cognitive loss From subjective memory complaints (SMC) to dementia Case 1. AR. 64 yrs Male GP referral

More information

Form D1: Clinician Diagnosis

Form D1: Clinician Diagnosis Initial Visit Packet Form D: Clinician Diagnosis NACC Uniform Data Set (UDS) ADC name: Subject ID: Form date: / / Visit #: Examiner s initials: INSTRUCTIONS: This form is to be completed by the clinician.

More information

WHAT IS DEMENTIA? An acquired syndrome of decline in memory and other cognitive functions sufficient to affect daily life in an alert patient

WHAT IS DEMENTIA? An acquired syndrome of decline in memory and other cognitive functions sufficient to affect daily life in an alert patient DEMENTIA WHAT IS DEMENTIA? An acquired syndrome of decline in memory and other cognitive functions sufficient to affect daily life in an alert patient Progressive and disabling Not an inherent aspect of

More information

What APS Workers Need to Know about Frontotemporal, Lewy Body and Vascular Dementias

What APS Workers Need to Know about Frontotemporal, Lewy Body and Vascular Dementias What APS Workers Need to Know about Frontotemporal, Lewy Body and Vascular Dementias Presenter: Kim Bailey, MS Gerontology, Program & Education Specialist, Alzheimer s Orange County 1 1 Facts About Our

More information

Neuropsychiatric Manifestations in Vascular Cognitive Impairment Patients with and without Dementia

Neuropsychiatric Manifestations in Vascular Cognitive Impairment Patients with and without Dementia 86 Neuropsychiatric Manifestations in Vascular Cognitive Impairment Patients with and without Dementia Pai-Yi Chiu 1,3, Chung-Hsiang Liu 2, and Chon-Haw Tsai 2 Abstract- Background: Neuropsychiatric profile

More information

Correlation between motor and cognitive functions in the progressive course of Parkinson s disease

Correlation between motor and cognitive functions in the progressive course of Parkinson s disease doi:10.1111/ncn3.53 ORIGINAL ARTICLE Correlation between motor and cognitive functions in the progressive course of Parkinson s disease Hidetomo Murakami,* Yoshiyuki Owan,* Yukiko Mori,* Kazuhisa Fujita,*

More information

Behavioral Aspects of Parkinson s Disease

Behavioral Aspects of Parkinson s Disease Behavioral Aspects of Parkinson s Disease Joseph H. Friedman, MD Director, Movement Disorders Program Butler Hospital Dept of Neurology Alpert Medical School of Brown University 1 Disclosures Drugs will

More information

Basal ganglia motor circuit

Basal ganglia motor circuit Parkinson s Disease Basal ganglia motor circuit 1 Direct pathway (gas pedal) 2 Indirect pathway (brake) To release or augment the tonic inhibition of GPi on thalamus Direct pathway There is a tonic inhibition

More information

The Neuropsychology of

The Neuropsychology of The Neuropsychology of Stroke Tammy Kordes, Ph.D. Northshore Neurosciences Outline What is the Role of Neuropsychology Purpose of Neuropsychological Assessments Common Neuropsychological Disorders Assessment

More information

Palliative Approach to the Person with Advanced Dementia

Palliative Approach to the Person with Advanced Dementia Mid North Coast Rural Palliative Care Project Link Nurse Education 2004 Palliative Approach to the Person with Advanced Dementia Anne Sneesby CNC - ACAT To care for the dying is a very human opportunity

More information

ORIGINAL CONTRIBUTION. Progression of Dysarthria and Dysphagia in Postmortem-Confirmed Parkinsonian Disorders

ORIGINAL CONTRIBUTION. Progression of Dysarthria and Dysphagia in Postmortem-Confirmed Parkinsonian Disorders ORIGINAL CONTRIBUTION Progression of Dysarthria and Dysphagia in Postmortem-Confirmed Parkinsonian Disorders Jörg Müller, MD; Gregor K. Wenning, MD, PhD; Marc Verny, MD; Ann McKee, MD; K. Ray Chaudhuri,

More information

Perspectives on Frontotemporal Dementia and Primary Progressive Aphasia

Perspectives on Frontotemporal Dementia and Primary Progressive Aphasia Perspectives on Frontotemporal Dementia and Primary Progressive Aphasia Bradley F. Boeve, M.D. Division of Behavioral Neurology Department of Neurology Mayo Clinic Rochester, Minnesota Alzheimer s Disease

More information

Dementia. Stephen S. Flitman, MD Medical Director 21st Century Neurology

Dementia. Stephen S. Flitman, MD Medical Director 21st Century Neurology Dementia Stephen S. Flitman, MD Medical Director 21st Century Neurology www.neurozone.org Dementia is a syndrome Progressive memory loss, plus Progressive loss of one or more cognitive functions: Language

More information

Cognitive and motor assessment in autopsy-proven corticobasal degeneration

Cognitive and motor assessment in autopsy-proven corticobasal degeneration Cognitive and motor assessment in autopsy-proven corticobasal degeneration R. Murray, BS; M. Neumann, MD; M.S. Forman, MD, PhD; J. Farmer, MSc; L. Massimo, LPN; A. Rice, BS; B.L. Miller, MD; J.K. Johnson,

More information

Overview. Overview. Parkinson s disease. Secondary Parkinsonism. Parkinsonism: Motor symptoms associated with impairment in basal ganglia circuits

Overview. Overview. Parkinson s disease. Secondary Parkinsonism. Parkinsonism: Motor symptoms associated with impairment in basal ganglia circuits Overview Overview Parkinsonism: Motor symptoms associated with impairment in basal ganglia circuits The differential diagnosis of Parkinson s disease Primary vs. Secondary Parkinsonism Proteinopathies:

More information

Frontal Behavioural Inventory (FBI)

Frontal Behavioural Inventory (FBI) This is a Sample version of the Frontal Behavioural Inventory (FBI) The full version of the Frontal Behavioural Inventory (FBI) comes without sample watermark. The full complete version includes Complete

More information

DSM-5 MAJOR AND MILD NEUROCOGNITIVE DISORDERS (PAGE 602)

DSM-5 MAJOR AND MILD NEUROCOGNITIVE DISORDERS (PAGE 602) SUPPLEMENT 2 RELEVANT EXTRACTS FROM DSM-5 The following summarizes the neurocognitive disorders in DSM-5. For the complete DSM-5 see Diagnostic and Statistical Manualof Mental Disorders, 5th edn. 2013,

More information

Dementia. Assessing Brain Damage. Mental Status Examination

Dementia. Assessing Brain Damage. Mental Status Examination Dementia Assessing Brain Damage Mental status examination Information about current behavior and thought including orientation to reality, memory, and ability to follow instructions Neuropsychological

More information

Use of the Neuropsychiatric Inventory to Characterize the Course of Neuropsychiatric Symptoms in Progressive Supranuclear Palsy

Use of the Neuropsychiatric Inventory to Characterize the Course of Neuropsychiatric Symptoms in Progressive Supranuclear Palsy ARTICLES Use of the Neuropsychiatric Inventory to Characterize the Course of Neuropsychiatric Symptoms in Progressive Supranuclear Palsy Milica Jecmenica-Lukic, M.D., Tatjana Pekmezovic, M.D., Ph.D., Igor

More information

Huntington s Disease Psychiatry. Christopher A. Ross MD PhD HDSA Convention June 6, Many slides adapted from Adam Rosenblatt, MD

Huntington s Disease Psychiatry. Christopher A. Ross MD PhD HDSA Convention June 6, Many slides adapted from Adam Rosenblatt, MD Huntington s Disease Psychiatry Christopher A. Ross MD PhD HDSA Convention June 6, 2008 --Many slides adapted from Adam Rosenblatt, MD Huntington s Disease Society of America The information provided by

More information

Evolution of a concept: Apraxia/higher level gait disorder. ataxia v. apraxia gait = limb apraxia. low, middle, high gait disturbance levels

Evolution of a concept: Apraxia/higher level gait disorder. ataxia v. apraxia gait = limb apraxia. low, middle, high gait disturbance levels Case #1 81-year-old woman Gait Imbalance: Two Unusual Cases in Older Patients February 2008: 3 years of gradually progressive gait imbalance no vertigo, dizziness or paresthesias etiology unclear on examination

More information

P20.2. Characteristics of different types of dementia and challenges for the clinician

P20.2. Characteristics of different types of dementia and challenges for the clinician P20.2. Characteristics of different types of dementia and challenges for the clinician, professor Danish Dementia Research Center Rigshospitalet, University of Copenhagen (Denmark) This project has received

More information

DISCLAIMER: ECHO Nevada emphasizes patient privacy and asks participants to not share ANY Protected Health Information during ECHO clinics.

DISCLAIMER: ECHO Nevada emphasizes patient privacy and asks participants to not share ANY Protected Health Information during ECHO clinics. DISCLAIMER: Video will be taken at this clinic and potentially used in Project ECHO promotional materials. By attending this clinic, you consent to have your photo taken and allow Project ECHO to use this

More information

Mild Cognitive Impairment (MCI)

Mild Cognitive Impairment (MCI) October 19, 2018 Mild Cognitive Impairment (MCI) Yonas E. Geda, MD, MSc Professor of Neurology and Psychiatry Consultant, Departments of Psychiatry & Psychology, and Neurology Mayo Clinic College of Medicine

More information

FRONTOTEMPORAL DEGENERATION: OVERVIEW, TRENDS AND DEVELOPMENTS

FRONTOTEMPORAL DEGENERATION: OVERVIEW, TRENDS AND DEVELOPMENTS FRONTOTEMPORAL DEGENERATION: OVERVIEW, TRENDS AND DEVELOPMENTS Norman L. Foster, M.D. Director, Center for Alzheimer s Care, Imaging and Research Chief, Division of Cognitive Neurology, Department of Neurology

More information

Update on functional brain imaging in Movement Disorders

Update on functional brain imaging in Movement Disorders Update on functional brain imaging in Movement Disorders Mario Masellis, MSc, MD, FRCPC, PhD Assistant Professor & Clinician-Scientist Sunnybrook Health Sciences Centre University of Toronto 53 rd CNSF

More information

Dementia in Parkinson s disease:

Dementia in Parkinson s disease: Dementia in Parkinson s disease: A 20 year Prospective Neuropsychological Study Sydney Multicentre Study Associate Professor Wayne GJ Reid PhD FAPS 149 newly diagnosed community living Parkinson s Disease

More information

The origins of localization

The origins of localization Association Cortex, Asymmetries, and Cortical Localization of Affective and Cognitive Functions Michael E. Goldberg, M.D. The origins of localization The concept that different parts of the brain did different

More information

Alzheimer s Disease. Clinical characteristics of late-onset Alzheimer s disease (LOAD) A/Prof David Darby

Alzheimer s Disease. Clinical characteristics of late-onset Alzheimer s disease (LOAD) A/Prof David Darby Alzheimer s Disease Clinical characteristics of late-onset Alzheimer s disease (LOAD) A/Prof David Darby Florey Institute of Neuroscience and Mental Health 28-6-2013 The burden of late-onset Alzheimer

More information

Association Cortex, Asymmetries, and Cortical Localization of Affective and Cognitive Functions. Michael E. Goldberg, M.D.

Association Cortex, Asymmetries, and Cortical Localization of Affective and Cognitive Functions. Michael E. Goldberg, M.D. Association Cortex, Asymmetries, and Cortical Localization of Affective and Cognitive Functions Michael E. Goldberg, M.D. The origins of localization The concept that different parts of the brain did different

More information

AGED SPECIFIC ASSESSMENT TOOLS. Anna Ciotta Senior Clinical Neuropsychologist Peninsula Mental Health Services

AGED SPECIFIC ASSESSMENT TOOLS. Anna Ciotta Senior Clinical Neuropsychologist Peninsula Mental Health Services AGED SPECIFIC ASSESSMENT TOOLS Anna Ciotta Senior Clinical Neuropsychologist Peninsula Mental Health Services Issues in assessing the Elderly Association between biological, psychological, social and cultural

More information

Chronic Effects of Dopaminergic Replacement on Cognitive Function in Parkinson s Disease: A Two-Year Follow-Up Study of Previously Untreated Patients

Chronic Effects of Dopaminergic Replacement on Cognitive Function in Parkinson s Disease: A Two-Year Follow-Up Study of Previously Untreated Patients Movement Disorders Vol. 15, No. 4, 2000, pp. 613 626 2000 Movement Disorder Society Chronic Effects of Dopaminergic Replacement on Cognitive Function in Parkinson s Disease: A Two-Year Follow-Up Study

More information

ORIGINAL CONTRIBUTION. Accuracy of the Clinical Diagnoses of Lewy Body Disease, Parkinson Disease, and Dementia With Lewy Bodies

ORIGINAL CONTRIBUTION. Accuracy of the Clinical Diagnoses of Lewy Body Disease, Parkinson Disease, and Dementia With Lewy Bodies Accuracy of the Clinical Diagnoses of Lewy Body Disease, Parkinson Disease, and Dementia With Lewy Bodies A Clinicopathologic Study ORIGINAL CONTRIBUTION I. Litvan, MD; A. MacIntyre, MHS; C. G. Goetz,

More information

T he prevalence of Parkinson s disease (PD) is nearly 1% in

T he prevalence of Parkinson s disease (PD) is nearly 1% in 708 PAPER Donepezil for cognitive impairment in Parkinson s disease: a randomised controlled study D Aarsland, K Laake, J P Larsen, C Janvin... See end of article for authors affiliations... Correspondence

More information

Two Cases of Palilalia

Two Cases of Palilalia Two Cases of Palilalia Hyanghee Kim, Ph.D., Soo-Jin Cho, M.D., Won-Yong Lee, M.D., Duk L. Na, M.D., Kwang-Ho Lee, M.D. Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of

More information

Role of Neuropsychiatric Assessment in Diagnosis and Research

Role of Neuropsychiatric Assessment in Diagnosis and Research Role of Neuropsychiatric Assessment 163 11 Role of Neuropsychiatric Assessment in Diagnosis and Research Dag Aarsland, Uwe Ehrt, and Clive Ballard INTRODUCTION Although the basal ganglia have traditionally

More information

Lecture 35 Association Cortices and Hemispheric Asymmetries -- M. Goldberg

Lecture 35 Association Cortices and Hemispheric Asymmetries -- M. Goldberg Lecture 35 Association Cortices and Hemispheric Asymmetries -- M. Goldberg The concept that different parts of the brain did different things started with Spurzheim and Gall, whose phrenology became quite

More information

correlates with social context behavioral adaptation.

correlates with social context behavioral adaptation. REVIEW OF FRONTAL LOBE STRUCTURES Main organization of frontal cortex: 1. Motor area (precentral gyrus). 2. Premotor & supplementary motor areas (immediately anterior to motor area). Includes premotor,

More information

WEBINAR SERIES: AGING IN INDIVIDUALS WITH INTELLECTUAL AND DEVELOPMENTAL DISABILITIES

WEBINAR SERIES: AGING IN INDIVIDUALS WITH INTELLECTUAL AND DEVELOPMENTAL DISABILITIES WEBINAR SERIES: AGING IN INDIVIDUALS WITH INTELLECTUAL AND DEVELOPMENTAL DISABILITIES 1 CMS Medicare-Medicaid Coordination Office (MMCO) Established by Section 2602 of the Affordable Care Act Purpose:

More information

Parkinson s Disease. Sirilak yimcharoen

Parkinson s Disease. Sirilak yimcharoen Parkinson s Disease Sirilak yimcharoen EPIDEMIOLOGY ~1% of people over 55 years Age range 35 85 years peak age of onset is in the early 60s ~5% of cases characterized by an earlier age of onset (typically

More information

Alzheimer s disease dementia: a neuropsychological approach

Alzheimer s disease dementia: a neuropsychological approach Alzheimer s disease dementia: a neuropsychological approach Dr. Roberta Biundo, PhD Neuropsychology Coordinator at Parkinson s disease and movement disorders unit of San Camillo rehabilitation hospital

More information

Functional Neuroanatomy and Traumatic Brain Injury The Frontal Lobes

Functional Neuroanatomy and Traumatic Brain Injury The Frontal Lobes Functional Neuroanatomy and Traumatic Brain Injury The Frontal Lobes Jessica Matthes, Ph.D., ABN Barrow TBI Symposium March 23, 2019 jessica.matthes@dignityhealth.org Outline TBI Mechanisms of Injury Types

More information

DEMENTIA? 45 Million. What is. WHAT IS DEMENTIA Dementia is a disturbance in a group of mental processes including: 70% Dementia is not a disease

DEMENTIA? 45 Million. What is. WHAT IS DEMENTIA Dementia is a disturbance in a group of mental processes including: 70% Dementia is not a disease What is PRESENTS DEMENTIA? WHAT IS DEMENTIA Dementia is a disturbance in a group of mental processes including: Memory Reasoning Planning Learning Attention Language Perception Behavior AS OF 2013 There

More information

A Fresh View of Cognitive Disorders in Older Adults: New Classification and Screening Strategies

A Fresh View of Cognitive Disorders in Older Adults: New Classification and Screening Strategies A Fresh View of Cognitive Disorders in Older Adults: New Classification and Screening Strategies Lynda Mackin, PhD, AGPCNP-BC, CNS University of California San Francisco School of Nursing 1 Alzheimer s

More information

NIH Public Access Author Manuscript Mov Disord. Author manuscript; available in PMC 2009 May 18.

NIH Public Access Author Manuscript Mov Disord. Author manuscript; available in PMC 2009 May 18. NIH Public Access Author Manuscript Published in final edited form as: Mov Disord. 2008 August 15; 23(11): 1602 1605. doi:10.1002/mds.22161. Emergence of Parkinsons Disease in Essential Tremor: A Study

More information

Overview. Case #1 4/20/2012. Neuropsychological assessment of older adults: what, when and why?

Overview. Case #1 4/20/2012. Neuropsychological assessment of older adults: what, when and why? Neuropsychological assessment of older adults: what, when and why? Benjamin Mast, Ph.D. Associate Professor & Vice Chair, Psychological & Brain Sciences Associate Clinical Professor, Family & Geriatric

More information

M P---- Ph.D. Clinical Psychologist / Neuropsychologist

M P---- Ph.D. Clinical Psychologist / Neuropsychologist M------- P---- Ph.D. Clinical Psychologist / Neuropsychologist NEUROPSYCHOLOGICAL EVALUATION Name: Date of Birth: Date of Evaluation: 05-28-2015 Tests Administered: Wechsler Adult Intelligence Scale Fourth

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy Dopamine Transporter Imaging with Single Photon Emission File Name: Origination: Last CAP Review: Next CAP Review: Last Review: dopamine_transporter_imaging_with_single_photon_emission_computed_tomography

More information

Behavioral and psychological symptoms of dementia characteristic of mild Alzheimer patients

Behavioral and psychological symptoms of dementia characteristic of mild Alzheimer patients Blackwell Science, LtdOxford, UKPCNPsychiatry and Clinical Neurosciences1323-13162005 Blackwell Publishing Pty Ltd593274279Original ArticleDementia and mild AlzheimersJ. Shimabukuro et al. Psychiatry and

More information

I n the past three decades various cognitive screening

I n the past three decades various cognitive screening 700 PAPER The seven minute screen: a neurocognitive screening test highly sensitive to various types of dementia E F J Meulen, B Schmand, J P van Campen, S J de Koning, R W Ponds, P Scheltens, F R Verhey...

More information

Test Assessment Description Ref. Global Deterioration Rating Scale Dementia severity Rating scale of dementia stages (2) (4) delayed recognition

Test Assessment Description Ref. Global Deterioration Rating Scale Dementia severity Rating scale of dementia stages (2) (4) delayed recognition Table S. Cognitive tests used in the Georgia Centenarian Study. Test Assessment Description Ref. Mini-Mental State Examination Global cognitive performance A brief screening of orientation, memory, executive

More information

Recognition and Management of Behavioral Disturbances in Dementia

Recognition and Management of Behavioral Disturbances in Dementia Recognition and Management of Behavioral Disturbances in Dementia Danielle Hansen, DO, MS (Med Ed), MHSA INTRODUCTION 80% 90% of patients with dementia develop at least one behavioral disturbances or psychotic

More information